Alliancebernstein L.P. maintained its stake in Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 19,400 shares of the biopharmaceutical company’s stock at the end of the first quarter. Alliancebernstein L.P. owned about 0.07% of Bellicum Pharmaceuticals worth $239,000 at the end of the most recent reporting period.
Other large investors have also recently bought and sold shares of the company. Eagle Ridge Investment Management bought a new position in Bellicum Pharmaceuticals during the first quarter worth $144,000. American International Group Inc. increased its position in Bellicum Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 12,902 shares of the biopharmaceutical company’s stock worth $159,000 after buying an additional 852 shares in the last quarter. Fox Run Management L.L.C. bought a new position in Bellicum Pharmaceuticals during the first quarter worth $171,000. Trexquant Investment LP bought a new position in Bellicum Pharmaceuticals during the first quarter worth $211,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in Bellicum Pharmaceuticals during the first quarter worth $277,000. Hedge funds and other institutional investors own 63.97% of the company’s stock.
Bellicum Pharmaceuticals, Inc. (NASDAQ BLCM) traded down 0.51% on Thursday, reaching $7.87. 57,895 shares of the company traded hands. The stock’s market capitalization is $261.49 million. Bellicum Pharmaceuticals, Inc. has a 1-year low of $7.41 and a 1-year high of $23.11. The stock’s 50-day moving average is $10.90 and its 200-day moving average is $12.21.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.65) by $0.09. Bellicum Pharmaceuticals had a negative net margin of 17,957.31% and a negative return on equity of 70.74%. During the same quarter last year, the firm posted ($0.61) EPS. Equities research analysts expect that Bellicum Pharmaceuticals, Inc. will post ($3.00) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This report was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://stocknewstimes.com/2017/08/17/bellicum-pharmaceuticals-inc-blcm-position-held-by-alliancebernstein-l-p.html.
BLCM has been the subject of a number of research reports. Wells Fargo & Company reissued an “outperform” rating and set a $31.00 target price on shares of Bellicum Pharmaceuticals in a research report on Tuesday, June 27th. Raymond James Financial, Inc. reissued a “buy” rating on shares of Bellicum Pharmaceuticals in a research report on Tuesday, June 27th. Cantor Fitzgerald reissued an “overweight” rating and set a $35.00 target price on shares of Bellicum Pharmaceuticals in a research report on Monday, June 26th. BidaskClub downgraded shares of Bellicum Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, July 6th. Finally, Jefferies Group LLC reduced their target price on shares of Bellicum Pharmaceuticals from $19.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, May 9th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. Bellicum Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $26.20.
In other news, CFO Alan A. Musso sold 6,311 shares of the business’s stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $12.24, for a total transaction of $77,246.64. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider David M. Spencer sold 10,000 shares of the business’s stock in a transaction dated Monday, July 10th. The shares were sold at an average price of $11.54, for a total transaction of $115,400.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 30,571 shares of company stock worth $367,295. Corporate insiders own 23.30% of the company’s stock.
About Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
Want to see what other hedge funds are holding BLCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM).
Receive News & Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
